Early Access — free while we kick the tires
EdgarHawk

Shawver Laura

Director

Director
1 filing analyzed · 1 company · Latest 2024-12-04

Companies

Company Buys Sells Direction
ARS Pharmaceuticals, Inc. SPRY 0 9 Net selling

Activity

December 2024
high
Sell
200,000 shares
$2,688,751
Significance 7/10

Director Shawver sold 200,000 shares (48.7% of holdings) for $2.7M across four transactions Dec 2-4, blended avg $13.44

Director Laura Shawver executed four separate sales totaling 200,000 shares (200.0K shares) for $2,688,750.95 ($2.7M) over three trading days, reducing her holdings from 410,346 shares to 210,346 shares (a 48.7% reduction). The sales occurred at prices ($13.55, $14.34, $13.26, and $13.75) clustered around a blended average of $13.44, trading slightly below the current price of $14.42. In context of SPRY's fundamentals—latest quarterly revenue of $2,068,000.00 ($2.1M), annual net income of $-19,128,000.00 ($-19.1M), and annual revenue growth of -97.7%—the substantial liquidation of nearly half her position warrants investor attention, particularly given the company's unprofitability and severe revenue contraction. The stock's 52-week trading range of $4.83–$17.49 and recent 90-day appreciation of +22.7% provide context for the transaction prices, though the fundamental operational deterioration underscores the importance of understanding the sale's implications for governance and confidence in the business trajectory.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access